Australia allows Psilocybin and MDMA
Re-scheduling of psilocybin and MDMA
On 3 February 2023, TGA
Permit prescribing of MDMA for the treatment of post-traumatic stress disorder (PTSD)
Psilocybin for treatment-resistant depression (TRD)
Psychiatrists who are specifically authorised under the TGA’s Authorised Prescriber scheme,
effective from 1 July 2023.
Legal psilocybin prescriptions in Canada
(January 2022)
https://www.drugscience.org.uk/canadians-can-now-be-legally-prescribed-psilocybin/
The SAP allows healthcare practitioners to request limited access to drugs that are not authorized for sale in Canada.
https://www.psychiatrist.com/jcp/depression/identifying-difficult-treat-depression-differential/
Treatment-resistant depression (TRD) is common
Responsible for much of the burden of major depressive disorder worldwide.
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial
https://journals.sagepub.com/doi/10.1177/0269881116675512?url_ver=Z39.88-2003
Clinically significant anxiety and depression
Common in patients with cancer
Associated with poor psychiatric and medical outcomes
Double-blind, placebo-controlled trial
Intervention
Single-dose psilocybin (0.3 mg/kg),
70 Kg = 21mg
in conjunction with psychotherapy.
Assessed at 7 weeks
Psilocybin produced immediate, substantial, and sustained improvements in anxiety and depression,
and led to decreases in cancer-related demoralization and hopelessness,
improved spiritual wellbeing,
and increased quality of life.
At the 6.5-month follow-up
Psilocybin was associated with enduring anxiolytic and anti-depressant effects,
60–80% of participants continued with clinically significant reductions in depression or anxiety,
sustained benefits in existential distress and quality of life,
as well as improved attitudes towards death.
The psilocybin-induced mystical experience mediated the therapeutic effect of psilocybin on anxiety and depression.
Trial Registration: ClinicalTrials.gov Identifier: NCT00957359
Change to classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists
Medicines containing the psychedelic substances psilocybin,
and MDMA (3,4-methylenedioxy-methamphetamine)
Only conditions, currently sufficient evidence
For potential benefits in certain patients,
MDMA for treatment of post-traumatic stress disorder
Psilocybin for treatment-resistant depression
Acknowledges the current lack of options for patients with specific treatment-resistant mental illnesses
Patients may be vulnerable during psychedelic-assisted psychotherapy,
requiring controls to protect these patients.
There are currently no approved products containing psilocybin or MDMA that the TGA has evaluated for quality, safety and efficacy.
However, this amendment will allow authorised psychiatrists to access and legally supply a specified ’unapproved’ medicine containing these substances to patients under their care for these specific uses.
-
1:37
News And Media
1 year agoThe Potential Of Psilocybin For Mental Health Now 2023
5441 -
1:00
TrueLifepodcast
1 year agoPsychedelics - MDMA as a medicine
55 -
34:44
Leo & Longevity
2 months ago $0.03 earnedSSRIs vs. Psilocybin: Is Big Pharma Out to Get Us?
1321 -
2:13
The Brain's Eye
1 year ago🧠Resetting the brain? how psilocybin is being used to treat severe depression
31 -
30:15
Mind & Matter Podcast
10 months agoPsilocybin-Assisted Psychotherapy
33 -
2:30
MushieMan
10 months agoMicrodosing Psilocybin: Unveiling the Magic
38 -
3:37
Stoned Traders Club
6 months agoThe Surprising Health Benefits of Cannabis: Exploring its Medicinal Potential
1633 -
2:23
The Cannabis Experts
4 years agoHealth Service Approves Cannabis Based Medicines
30 -
1:22
tripsitter01
4 months agoTripsitter Psychedelics
30 -
55:59
DocSnipes
3 years agoNeurobiological Impact of Stimulants Depressants and Hallucinogens
98